CAPTRUST Financial Advisors
AVDL

CAPTRUST Financial Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-344
Closed -$1K – 2226
2022
Q2 		$1K Hold
344
– – ﹤0.01% 4627
2022
Q1 		$2K Buy
+344
New +$2.37K ﹤0.01% 4458

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

CAPTRUST Financial Advisors's AVDL Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q3 2022, closing a stake of 344 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in AVDL in Q1 2022 and held it in 2 quarters. The position peaked at $2K in Q1 2022. 76 funds tracked by Wall St. Rank hold AVDL as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Avadel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 344 Avadel Pharmaceuticals shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Avadel Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Avadel Pharmaceuticals position peaked at $2K in Q1 2022.
  • 76 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.